The Merz buyout of BFRM makes a lot of sense, but I was so focused on JNJ as a prospective BFRM suitor that I overlooked the move by Merz.
Merz will now have both the best neurotoxin and the best dermal filler on the market, which means they’ll benefit from cross-selling opportunities coming and going. Too bad we can't buy their stock.
Market Data 
Markets 
AI
